Baxter International Inc. unveiled favorable phase III data from the pivotal trial with BAX 855, an extended half-life recombinant factor VIII (rFVIII) antagonist for hemophilia A. The follow-on for Baxter's gold standard Advate (octocog alfa) is partnered with Nektar Therapeutics Inc., and analysts say the latest results put the companies on solid footing in the space.